ArticleGland surgery2021
Prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection.
Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is tumor necrosis a clinical prognostic factor in hepato-biliary-pancreatic cancers? A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Correlation between 18 F-FDG PET/CT, Gd-EOB-DTPA MRI combined with laboratory parameters and microvascular invasion, and the potential of nomogram to predict microvascular invasion of hepatocellular carcinoma before liver transplantation.Nuclear medicine communications · 2026Article
- A deep learning-based prognostic prediction model for distal cholangiocarcinoma incorporating the metabolism-inflammation marker monocyte-to-high-density lipoprotein cholesterol ratio.Translational cancer research · 2025Article
- Necessity and Reconstruction Methods of Splenic Vein After Resection of the Portomesenteric Junction During Resections for Pancreatic Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study.Annals of surgical treatment and research · 2025Article
- Tissue inhibitor of metalloproteinase 1 as a biomarker of venous invasion in pancreatic ductal adenocarcinoma.American journal of cancer research · 2025Article
- A multi-algorithm prognostic model combining inflammatory indices and surgical features in distal cholangiocarcinoma.Frontiers in oncology · 2025Article
- Monocyte to high-density lipoprotein ratio based prognostic nomogram for patients following allogeneic vascular replacement pancreaticoduodenectomy.Frontiers in genetics · 2024Article
- Interventional Management of Portal Hypertension in Cancer Patients.Current oncology reports · 2022Review
- Erratum to prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection.Gland surgery · 2022Article
- Without compromising surgical outcomes, neoadjuvant therapy might be a better approach to improve the prognosis of patients with advanced pancreatic cancer.Gland surgery · 2021Article
- Letter to the editor: the nonnegligible effect of neoadjuvant therapy for patients with borderline resectable pancreatic ductal adenocarcinoma.Gland surgery · 2021Article
- CA19-9 Level to Serum γ-Glutamyltransferase as a Potential Prognostic Biomarker in Patients with Pancreatic Head Carcinoma.Cancer management and research · 2021Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyze the related factors affecting the prognosis of pancreatic carcinoma with portal system invasion.
methodsWe retrospectively analyzed the clinical data of 118 patients with portal venous system invasion in Beijing Chaoyang Hospital between January 2011 and December 2018. Only patients with borderline resectable pancreatic cancer were included in this study. Borderline pancreatic cancer was defined according to NCCN (The National Comprehensive Cancer Network) guidelines. All patients underwent surgical treatment combined with vascular resection and reconstruction. The prognosis was evaluated according to the follow-up results, and the related risk factors for prognosis were analyzed. The survival curve was drawn by Kaplan-Meier method, and the survival rate was compared by log-rank test. Multivariate Cox regression was used to analyze the prognostic factors.
resultsIn our research, all of 126 patients were successfully completed the operations. Complications occurred in 29.7% of patients and perioperative death in 4.0%. A total of 118 patients were followed up and the followed-up rate was 97.5% (118/121). The overall 1-year, 2-year and 3-year survival rates were 49.2%, 27.1% and 19.8%, And the median survival time was 20 months. Multivariate analysis showed that preoperative CA19-9 (RR 1.449, 95% CI: 1.053-1.994), N status (RR 2.533, 95% CI: 1.337-4.798), degree of tumor differentiation (RR 1.592, 95% CI: 1.064-2.381) and venous invasion depth (RR 2.03, 95% CI: 1.504-2.758) were independent risk factors for the prognosis.
conclusionsThe long-term prognosis of pancreatic carcinoma patients with portal system invasion is poor. The venous invasion depth is an independent risk factor for the prognosis of pancreatic carcinoma with portal system invasion, the deeper of venous invasion, the worse the prognosis, and poorly differentiated tumors have the worst prognosis. Other independent risk factors included N status and the preoperative CA19-9. Those may help with patients' selection for different treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.